Table 1 Clinical features of patients in training and validation cohorts
Characteristics | Training cohort (n = 210) | Validation cohort (n = 90) | P-value | |
|---|---|---|---|---|
Gender (n, %) | Male | 148 (70.48) | 64 (71.11) | 0.912 |
Female | 62 (29.52) | 26 (28.89) | ||
CRM status (n, %) | Negative | 161 (76.67) | 67 (74.44) | 0.68 |
Positive | 49 (23.33) | 23 (25.56) | ||
Mri-EMVI status (n, %) | Negative | 161 (76.67) | 64 (71.11) | 0.309 |
Positive | 49 (23.33) | 26 (28.89) | ||
ACI status (n, %) | Negative | 201 (95.71) | 83 (92.22) | 0.34 |
Positive | 9 (4.29) | 7 (7.78) | ||
Lymph Node (n, %) | No metastasis | 78 (37.14) | 33 (36.67% | 0.938 |
Metastasis | 132 (62.86) | 57 (63.33) | ||
Tumor stage (n, %) | T1-T2 | 63 (30.00) | 17 (18.89) | 0.046 |
T3-T4 | 147 (70.00) | 73 (81.11) | ||
Age (years) | 64.19 ± 10.47 | 64.13 ± 9.73 | 0.965 | |
CEA (ng/mL) | 10.13 ± 39.74 | 12.63 ± 37.67 | 0.613 | |
Tumor size (cm3) | 17.63 ± 20.04 | 21.63 ± 32.62 | 0.195 | |
Dis (cm) | 8.02 ± 3.77 | 7.98 ± 3.65 | 0.934 | |